JP7603199B2 - 重水素を含有する化合物 - Google Patents

重水素を含有する化合物 Download PDF

Info

Publication number
JP7603199B2
JP7603199B2 JP2021521145A JP2021521145A JP7603199B2 JP 7603199 B2 JP7603199 B2 JP 7603199B2 JP 2021521145 A JP2021521145 A JP 2021521145A JP 2021521145 A JP2021521145 A JP 2021521145A JP 7603199 B2 JP7603199 B2 JP 7603199B2
Authority
JP
Japan
Prior art keywords
melflufen
deuterium
iii
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521145A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020079165A5 (https=
JP2022512736A (ja
JP2022512736A5 (https=
Inventor
レーマン、フレドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides Innovation AB
Original Assignee
Oncopeptides Innovation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Innovation AB filed Critical Oncopeptides Innovation AB
Publication of JP2022512736A publication Critical patent/JP2022512736A/ja
Publication of JPWO2020079165A5 publication Critical patent/JPWO2020079165A5/ja
Publication of JP2022512736A5 publication Critical patent/JP2022512736A5/ja
Priority to JP2024107578A priority Critical patent/JP2024150488A/ja
Application granted granted Critical
Publication of JP7603199B2 publication Critical patent/JP7603199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021521145A 2018-10-18 2019-10-17 重水素を含有する化合物 Active JP7603199B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107578A JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1816998.7 2018-10-18
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1909695.7 2019-07-05
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107578A Division JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Publications (4)

Publication Number Publication Date
JP2022512736A JP2022512736A (ja) 2022-02-07
JPWO2020079165A5 JPWO2020079165A5 (https=) 2022-10-18
JP2022512736A5 JP2022512736A5 (https=) 2022-10-18
JP7603199B2 true JP7603199B2 (ja) 2024-12-20

Family

ID=68290247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521145A Active JP7603199B2 (ja) 2018-10-18 2019-10-17 重水素を含有する化合物
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503564A (ja) 2000-06-13 2004-02-05 オンコペプティド　アクチボラグ メルファラン誘導体及び癌の化学療法薬としてのその使用
JP2014512402A (ja) 2011-04-28 2014-05-22 オンコペプティデス エービー 細胞毒性ジペプチドの凍結乾燥調製物
JP2015535243A (ja) 2012-10-26 2015-12-10 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤
JP2016513084A (ja) 2013-02-05 2016-05-12 インファール・アクティエンゲゼルシャフト 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
JP2018515512A (ja) 2015-05-08 2018-06-14 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ ナイトロジェンマスタード誘導体の調製方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503564A (ja) 2000-06-13 2004-02-05 オンコペプティド　アクチボラグ メルファラン誘導体及び癌の化学療法薬としてのその使用
JP2014512402A (ja) 2011-04-28 2014-05-22 オンコペプティデス エービー 細胞毒性ジペプチドの凍結乾燥調製物
JP2015535243A (ja) 2012-10-26 2015-12-10 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤
JP2016513084A (ja) 2013-02-05 2016-05-12 インファール・アクティエンゲゼルシャフト 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
JP2018515512A (ja) 2015-05-08 2018-06-14 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ ナイトロジェンマスタード誘導体の調製方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARBESON, S.and TUNG, R.，Deuterium Medicinal Chemistry: A New Approach to Drug Discoveryand Development，MEDCHEM NEWS，2014年，pp.8-22，DOI:10.14894/MEDCHEM.24.2_8
Sawada, M. et al.，Chiral Recognition in Host-Guest Complexation Determined by the Enantiomer-Labeled Guest Method Using Fast Atom Bombardment Mass Spectrometry，Journal of the American Chemical Society ，1995年，Vol.117, No.29，pp.7726-7736
TUNG, R.，The Development of Deuterium-Containing Drugs，Innovations in pharmaceutical technology，2010年，Vol.32，pp.24-28

Also Published As

Publication number Publication date
US20210388024A1 (en) 2021-12-16
ZA202102492B (en) 2024-04-24
JP2022512736A (ja) 2022-02-07
US20250115637A1 (en) 2025-04-10
JP2024150488A (ja) 2024-10-23
DK3866931T3 (da) 2023-04-24
IL282231A (en) 2021-05-31
KR20210078487A (ko) 2021-06-28
PL3866931T3 (pl) 2023-06-19
WO2020079165A1 (en) 2020-04-23
ES2942468T3 (es) 2023-06-01
AU2019362389B2 (en) 2024-12-12
KR102848971B1 (ko) 2025-08-21
IL282231B2 (en) 2025-07-01
EP3866931B1 (en) 2023-02-15
MA53904A (fr) 2021-08-25
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
BR112021007060A2 (pt) 2021-07-20
FI3866931T3 (fi) 2023-05-10
HUE061801T2 (hu) 2023-08-28
CN112930214A (zh) 2021-06-08
CN112930214B (zh) 2025-05-16
EP3866931A1 (en) 2021-08-25
US12152087B2 (en) 2024-11-26
IL282231B1 (en) 2025-03-01
MX2021004474A (es) 2021-08-24
AU2019362389A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
JP7603199B2 (ja) 重水素を含有する化合物
KR101125932B1 (ko) (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
KR102762016B1 (ko) 니트록솔린 전구약물 및 이의 용도
US8779191B2 (en) Methods and compositions for preparing lisdexamfetamine and salts thereof
JP7642560B2 (ja) 新規な製剤
US10464933B2 (en) Solid state forms of dasatinib and processes for their preparation
CN114805478A (zh) 氘代拟肽类化合物及其用途
EP3626715A1 (en) Crystal of benzofuran derivative free base and preparation method
JP7561497B2 (ja) 結晶性ピリミジニル－３，８－ジアザビシクロ［３．２．１］オクタニルメタノン化合物およびその使用
RU2703725C1 (ru) Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
KR102750784B1 (ko) 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 제조방법 및 그 중간체
JP2022523385A (ja) アクリル含有核輸送モジュレーターおよびその使用
CN120774918A (zh) 蛋白降解剂类化合物及其制备方法、药物组合物和应用
HK40048606A (en) Compounds containing deuterium
HK40048606B (en) Compounds containing deuterium
EA045396B1 (ru) Соединения, содержащие дейтерий
EP3498712B1 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
EP3988171A1 (en) Mitochondrial permeability transition pore (mptp)-opening inhibitor, novel compound exhibiting mptp-opening inhibitory activity, and use therefor
HK40047998A (en) Nitroxoline prodrug and use thereof
WO2025064699A1 (en) Therapeutic uses for epimers of hexahydrocannabivarin, hexahydrocannabidivarin, hexahydrocannabinol, hexahydrocannabidiol, and other hydrogenated cannabinoids
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240904

R150 Certificate of patent or registration of utility model

Ref document number: 7603199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150